August 25, 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for ...

First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes - MuSK+, LRP4+, triple seronegative Supplemental Biologics License ...